Morepen reports record Q1 revenue, EBITDA up 207%, PAT up 394%

Morepen reports record Q1 revenue, EBITDA up 207%, PAT up 394%. The company posted its highest-ever quarterly revenue and earnings in Q1 FY27. EBITDA surged by 207% while PAT jumped 394% year-on-year. Its CDMO segment has entered full-scale commercialization, marking a key growth milestone.

📊 STOCKS: $MOREPENLAB | 🏢 SECTOR: Pharma | #HIGHIMPACT #Earnings